HOME > ACADEMIA

    ACADEMIA

    Upside in Decelerating Gx Arena

    Meiji Pharma Pursuing Low-Cost Strategy to Weather Storm in Generics Space, Overseas Plants Hold Key
    By Takashi Ebisawa and Tatsuya Otsuka

    Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…

    My Viewpoint on CEA

    Kenporen Director Kono: Apply CEA to Reimbursement Decisions Once Credible System Established

    The Japanese cost-effectiveness assessment (CEA) scheme should be applied not only to the price adjustments of drugs and medical devices…

    HTA Debates in 2018-2019

    Japan to Roll Out Cost-Effectiveness Assessment Scheme in April

    Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

    TRENDS

    Drug Makers on Hunt for “Mibyo” Biz Opportunities as Pricing Rules Get Stricter
    By Reiji Anasako

    With Japan’s tighter price control casting a chill over its pharma market, companies are setting their sights beyond the field of health insurance to carve out a new revenue stream, seeking opportunities in the business to tackle “mibyo” - a…

    COMMENTARY

    Generic Makers Shifting to Focus on “Specialty Area” Faced with Tougher Business Environment
    By Tatsuya Otsuka

    Driven by changes surrounding the Japanese generic drug market, generic companies are trying to shift from a “generic” to a “specialty” model for their main business, with more and more players steering their focus towards specialized areas to secure profits.The…

    COLUMN

    Is Japan’s Cost-Effectiveness Assessment Scheme Cost Effective?
    By Yoshinori Sagehashi

    It’s official. Japan has decided to move ahead with the introduction of a cost-effectiveness assessment (CEA) scheme in April. But people from all walks of life – industry, government officials and academics included - are wondering, “What about the cost…